Global and Japan Anti-inflammatory Biologics Market Insights, Forecast to 2027

The biologics used in Anti-inflammatory treatment – abatacept (Orencia), adalimumab (Humira), anakinra (Kineret), etanercept (Enbrel), infliximab (Remicade) and rituximab (Rituxan) – block triggers of inflammation. Biologics may be used alone or in combination with a traditional DMARD to treat autoimmune forms of arthritis, such as RA juvenile idiopathic arthritis (JIA), ankylosing spondylitis or psoriasis/psoriatic arthritis. Biologics are given as an injection or infusion, and as such, there is always a risk of an injection site reaction or an infusion reaction.

Market Analysis and Insights: Global and Japan Anti-inflammatory Biologics Market
This report focuses on global and Japan Anti-inflammatory Biologics market.
In 2020, the global Anti-inflammatory Biologics market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In Japan the Anti-inflammatory Biologics market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Anti-inflammatory Biologics Scope and Market Size
Anti-inflammatory Biologics market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Anti-inflammatory Biologics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For Japan market, this report focuses on the Anti-inflammatory Biologics market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in Japan.

Segment by Type
Synthetic Type
Biological Type

Segment by Application
Arthritis
Respiratory Diseases
Dermatology
Gastroenterology
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
AbbVie
Johnson & Johnson
Amgen Inc
AstraZeneca PLC
Pfizer, Inc
Novartis
Roche
Sun Pharmaceutical Industries Ltd
Sanofi
GlaxoSmithKline